* Cambridge Biotech Corp., of Worcester, Mass., received $3.25million from Abbott Laboratories, of Abbott Park, Ill., under anagreement granting Abbott a non-exclusive sublicense for thediagnostic use of certain HIV-related technology. The agreementresolves a dispute between the companies on whether certainproducts Abbott sells were covered by the sublicense.
* Cytogen Corp., of Princeton, N.J., received $1.47 million from anaffiliate of Fletcher Asset Management Inc., of New York, for thepurchase of 225,000 shares of common stock. Under an existingarrangement Cytogen has the option to sell Fletcher up to 670,000shares at a premium price.
(c) 1997 American Health Consultants. All rights reserved.